M&A / Deals Autoimmune disease biotech Odyssey sets terms for $225m IPO PharmaphorumAfter abandoning an IPO bid last year, Odyssey is trying again, emboldened by recent big-value listings that suggest 2026 could be a bumper year.Immunology & InflammationRead full story pharminent May 5, 2026 (Last updated: May 5, 2026) Pharmaphorum After abandoning an IPO bid last year, Odyssey is trying again, emboldened by recent big-value listings that suggest 2026 could be a bumper year. Immunology & Inflammation Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Cytospire hauls in $83M for a new type of T cell engagerNext: Latus Bio secures $97m in funding to boost gene therapy access Related Stories M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026 M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026
